29/03/2024

News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History

29/03/2024

Mar 29, 2024, 23:06 | Blog
Neil Ranasinghe: So proud to receive the Flames of Hope Honorary Fellowship from Cancer Research UK (CRUK)
Neil Ranasinghe, Lead Technical Author at London Stock Exchange, sharen on LinkedIn: “So proud to…
Mar 29, 2024, 22:52 | Blog
Victor Gonzalez: I have decided to invest part of my savings in Oncoheroes Biosciences through their current open crowdfunding investment round in CapitalCel
Victor Gonzalez, Senior Renewal Manager at Salesforce, made the following post on LinkedIn: I have…
Mar 29, 2024, 22:45 | Blog
We're beyond thrilled to join forces with Brittney’s Believers Foundation - Oncoheroes Biosciences
Oncoheroes Biosciences made the following post on LinkedIn: "Exciting Announcement! We're beyond thrilled to join…
Mar 29, 2024, 22:36 | Opinion
Richard Sullivan: If you have a ‘desire to see things as they are’ then we have to face some self-evident truths in cancer; that power, money, and technology dominate
Mar 29, 2024, 22:30 | Blog
Brendon Stiles: Let's talk about PACIFIC 2
Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology at Montefiore Health System, posted…
Mar 29, 2024, 19:49 | Insight
Piotr Wysocki: There is still no proof that proton beam therapy is superior to IMRT in terms of quality of life in patients with localized prostate cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital…
Mar 29, 2024, 19:38 | Blog
Natanel Barookhian: NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity
Natanel Barookhian, Founder of TECHU, shared a post on X: "Naveris first earned our attention and investment…
Mar 29, 2024, 19:30 | Insight
Maria Natalia Gandur Quiroga: New Insights on Bladder Cancer Invasion
Maria Natalia Gandur Quiroga shared on X/Twitter: "New Insights on Bladder Cancer Invasion. Unraveling a…
Mar 29, 2024, 18:54 | Insight
Shushan Hovsepyan: Exploring new drugs for ultra-rare cancers?
Shushan Hovsepyan, Pediatric Oncologist and Research Coordinator at Yeolyan Hematology and Oncology Center, posted on…
Mar 29, 2024, 18:40 | Insight
Jarushka Naidoo: Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+ NSCLC meets primary PFS endpoint
Jarushka Naidoo shared on X/Twitter: "Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+…
All: 28 Posts: 1 - 10